SCHEMBL4908387

SCHEMBL4908387

O=C(O)c1cc2cncnc2s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 3/20 0.42
GLA P06280 1/20 0.42
PKM P14618 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
GPR35 Q9HC97 3/20 0.41
BCL2L1 Q07817 1/20 0.41
HCAR2 Q8TDS4 2/20 0.39
SLC22A12 Q96S37 1/20 0.36
DAO P14920 4/20 0.36
MAPT P10636 1/20 0.36
PLK4 O00444 1/20 0.36
AURKA O14965 1/20 0.36
DAPK3 O43293 1/20 0.36
CHEK2 O96017 1/20 0.36
CDK1 P06493 1/20 0.36
PIM1 P11309 1/20 0.36
PRKACA P17612 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29728017 1.00 ALDH1A1 (0.42) ALDH1A1MEN1KMT2AKDM4EGLA
SCHEMBL30396687 0.84 DAPK3 (0.49) PLK4AURKADAPK3CHEK2CDK1
SCHEMBL5073476 0.84 DAPK3 (0.49) PLK4AURKADAPK3CHEK2CDK1
SCHEMBL4800245 0.83 CSNK2A1 (0.46) ALDH1A1KDM4EPKMMAPTCSNK1D
SCHEMBL6224494 0.80 POLB (0.42) ALDH1A1KDM4EPKMMAPTPLK4
SCHEMBL29941720 0.77 HSP90AB1 (0.44) CSNK2A1
SCHEMBL16637562 0.76 HCAR2 (0.34) HCAR2
SCHEMBL4801512 0.76 CLK1 (0.49) ALDH1A1KDM4EPKMDYRK1A
SCHEMBL30632260 0.74 DHPS (0.34) ALDH1A1MEN1KMT2AKDM4EMAPT
SCHEMBL25409122 0.74 ALDH1A1 (0.44) ALDH1A1MEN1KMT2AKDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250250283-A1 COMPOUND CAPABLE OF REGULATING AND CONTROLLING ACTIVITY OF 15-PGDH, AND PREPARATION METHOD THEREFOR SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2025-08-07 US disclosed
EP-3055313-A1 CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF Bayer Pharma Aktiengesellschaft (DE) 2016-08-17 EP disclosed
CN-104744446-A Hetero-aromatic compound and application thereof in medicine GUANGDONG HEC PHARMACEUTICAL 2015-07-01 CN disclosed
WO-2015052065-A1 CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-04-16 WO disclosed
CN-104011054-A Thieno- and furo-pyrimidines and pyridines, useful as potassium channel inhibitors XENTION LTD 2014-08-27 CN disclosed
CN-102869669-A Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions BOEHRINGER INGELHEIM INT 2013-01-09 CN disclosed
US-20080108611-A1 SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-08 US disclosed
US-20050004126-A1 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors ANDRIANJARA CHARLES (FR) 2005-01-06 US disclosed
CN-1177848-C Bicyclic heteroaromatic compounds useful as LH agonists ��˹��ŵ�� 2004-12-01 CN disclosed
EP-1370562-A1 THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-12-17 EP disclosed
WO-2002064598-A1 THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed
CN-1349535-A Bicyclic heteroaromatic compounds useful as LH agonists AKZO NOBEL NV (NL) 2002-05-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004126-A1 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors MMP13, MMP12, MMP25 ALDH1A1 4241/4885MEN1 1184/4885KMT2A 2962/4885
US-20080108611-A1 SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS MAP4K2, MAP3K6, MAP3K2 ALDH1A1 1988/4885MEN1 3750/4885KMT2A 1506/4885
US-20250250283-A1 COMPOUND CAPABLE OF REGULATING AND CONTROLLING ACTIVITY OF 15-PGDH, AND PREPARATION METHOD THEREFOR CYP11B1, CYP51A1, CYP11B2 ALDH1A1 242/4885MEN1 2974/4885KMT2A 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.